New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
10:36 EDTCYTK, SRPT, FIO, DECK, CREEOptions with decreasing implied volatility: CYTK SRPT FIO DECK CREE
News For CYTK;SRPT;FIO;DECK;CREE From The Last 14 Days
Check below for free stories on CYTK;SRPT;FIO;DECK;CREE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
11:40 EDTCREECree drops, levels to watch
Subscribe for More Information
09:59 EDTCREEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTCREEOn The Fly: Pre-market Movers
Subscribe for More Information
07:21 EDTCYTKHeart Failure Society of America to hold annual meeting
Subscribe for More Information
05:37 EDTCREEAcuity Brands upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Acuity Brands to Buy saying growth in the company's LED lighting business is averaging over two-times the industry. Goldman is bullish on LED lighting adoption and raised its price target for shares to $153 from $128. The firm coupled the upgrade of Acuity with a downgrade of Cree (CREE) to Neutral.
05:35 EDTCREECree downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Cree (CREE) to Neutral citing slowing growth in the company's chip business. Goldman lowered its price target for Cree shares to $48 and $60 and prefers Acuity Brands (AYI) as an LED lighting investment. Shares of Cree closed Friday down 57c to $42.67. Goldman upgraded Acuity Brands this morning to Buy.
September 12, 2014
10:00 EDTCREEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
September 11, 2014
18:12 EDTCREECree initiated with a Market Perform at Cowen
Subscribe for More Information
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
September 9, 2014
10:13 EDTCREECree calls active on takeover speculation
Subscribe for More Information
09:52 EDTCREERumor: Cree strength attributed to takeover speculation
September 4, 2014
13:17 EDTSRPTSarepta rises after FDA seeks comment on proposed DMD drug guidance
Subscribe for More Information
12:54 EDTSRPTSarepta strength attributed to circulation of DMD guidance document
Reference Link
September 3, 2014
17:49 EDTDECKDeckers Outdoor CEO sold 40K shares for $3.71M, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use